Center of Excellence for Individualization of Therapy for Breast Cancer
Abstract
Optimal systemic treatment after breast cancer is the most crucial factor in reducing mortality in women with breast cancer. Adjuvant chemotherapy and hormonal treatment both reduce the risk of death in breast cancer patients. However, while estrogen receptors status predicts for response to hormone treatments, there are no clinically useful predictive markers for chemotherapy responses. All eligible women are therefore treated in the same manner. Even denoval drug resistance will result in treatment failures in many breast cancer patients. Currently, there are no methods available to distinguish those patients who are likely to respond to specific chemotherapies, and given the accepted practice of prescribing adjuvant treatment to most parties, even if the average expected benefit is slow, the selection of appropriate patients represents a major advance in the clinical management of breast cancer today.
Document Details
- Document Type
- Technical Report
- Publication Date
- Apr 01, 2007
- Accession Number
- ADA472068
Entities
People
- George W. Sledge
Organizations
- Indiana University